Oncaspar (Pegaspargase)

What it is and what it treats

Oncaspar contains pegaspargase, a form of the enzyme L-asparaginase modified by attachment of polyethylene glycol (PEG) chains. The enzyme breaks down the amino acid asparagine in the bloodstream; because certain leukaemic cells cannot synthesise their own asparagine, depleting the circulating supply selectively deprives these cells of a nutrient needed for protein synthesis and survival.

Oncaspar is approved as a component of multi-agent chemotherapy regimens for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric and adult patients, including as first-line therapy and in patients who have developed hypersensitivity to native (non-pegylated) forms of asparaginase derived from E. coli.

It is not used as monotherapy; it is administered alongside other chemotherapy agents according to institutional or cooperative-group ALL treatment protocols, under the supervision of a haematologist or paediatric oncologist.

Presentations and dosage forms

• Solution for injection/infusion, 3,750 IU per 5 mL single-use vial
• Administered by intramuscular injection or intravenous infusion, according to the approved label and clinical circumstances
• Supplied as a ready-to-use aqueous solution; the label advises against vigorous shaking during handling

How it is administered

The approved label describes a typical dose of 2,500 IU/m² given by intramuscular injection or intravenous infusion no more frequently than every 14 days, reflecting the drug's extended half-life compared with native asparaginase. This schedule is applied across induction, consolidation and delayed-intensification phases of ALL treatment protocols as directed by the treating team.

When given intramuscularly, the label recommends a maximum volume per injection site with the use of multiple sites if the total volume exceeds that limit. When given intravenously, the label describes infusion over approximately one to two hours, often preferred in patients with low platelet counts or other bleeding risk. Premedication with antihistamines or corticosteroids may be considered per local protocol to reduce the likelihood of infusion-related reactions.

Patients are typically observed for a period after administration because of the potential for hypersensitivity reactions, and the label describes emergency treatment (such as epinephrine) being available during administration. Ongoing laboratory monitoring — including liver function, coagulation studies, blood glucose and, where symptomatic, pancreatic enzymes — is described as part of routine care during treatment.

Storage and handling

• Store vials at 2–8 °C in a refrigerator
• Do not freeze; discard the vial if it has been frozen
• Protect from excessive agitation — do not shake vigorously during handling
• Keep the vial in its outer carton to protect from light
• Do not use beyond the expiry date stated on the packaging

Side effects

The following effects are described in the approved prescribing information for pegaspargase. Monitoring and management are directed by the treating haematology-oncology team.

Commonly reported

Serious effects requiring medical attention

Patients or caregivers should seek immediate medical attention for difficulty breathing, swelling, severe abdominal pain, signs of a blood clot (such as leg swelling or chest pain), or unusual bruising or bleeding. Suspected adverse reactions should be reported to national pharmacovigilance systems.

Pegaspargase vs native E. coli asparaginase vs Erwinia asparaginase

Three main forms of asparaginase enzyme therapy have been used in ALL treatment: native E. coli-derived asparaginase, pegaspargase (Oncaspar), and Erwinia-derived asparaginase (sourced from Erwinia chrysanthemi). All three deplete circulating asparagine, but they differ in immunogenicity, half-life and dosing frequency.

Pegaspargase's PEGylation reduces its immunogenicity relative to native E. coli asparaginase, which is associated with a lower rate of neutralising antibody formation and hypersensitivity reactions, and extends its half-life from roughly 1.2 days for native E. coli asparaginase to approximately 5.5 days for pegaspargase — allowing less frequent dosing (about every 14 days rather than several times per week).

Erwinia-derived asparaginase is immunologically distinct from the E. coli-derived enzymes and is generally reserved, per treatment protocols, for patients who develop hypersensitivity to E. coli-derived products (native or pegylated), since its different bacterial origin reduces cross-reactivity. Choice between these three options is determined by the treating haematology-oncology team based on treatment phase, prior hypersensitivity history and institutional protocol.

Availability and supply route

Oncaspar's registration status varies by country; it is approved by the FDA and by the EMA in the European Union, with authorisation status and available pack sizes differing elsewhere. Treatment centres should confirm current local registration and any named-patient requirements before planning a course of therapy.

As a specialist oncology biologic, Oncaspar is supplied and administered only against a valid prescription issued by a haematologist or oncologist, typically within a hospital setting equipped for chemotherapy administration and management of hypersensitivity reactions. Where the product is not locally registered, named-patient supply frameworks may allow import of a specific patient's prescribed treatment under national pharmacovigilance and import rules.

Pharmacy Remedy is a licensed Turkish pharmaceutical wholesaler operating within the regulated depot and distribution channel; it supplies healthcare institutions and licensed pharmacies against valid documentation and does not sell prescription medicines directly to members of the public.

Frequently asked questions

Primary sources

• EMA — Oncaspar product information
• FDA — Oncaspar prescribing information

Further reading and regulatory routes

• How to verify a medicine is genuine
• Why medicines cost less in Türkiye
• WHO falsified medicine alerts
• Named patient supply
• UAE import guide
• For healthcare professionals
• All medicine monographs

Related medicines

• Keytruda (pembrolizumab)
• Opdivo (nivolumab)
• Kyprolis (carfilzomib)